Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
Sponsored by NGM Biopharmaceuticals, Inc
About this trial
Last updated 7 years ago
Study ID
15-0106
Status
Completed
Type
Interventional
Phase
Phase 2
Placebo
Yes
Accepting
18 to 75 Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 8 years ago
What is this trial about?
The purpose of this study is to determine the safety, tolerability, and activity of
NGM282 in patients with Primary Sclerosing Cholangitis.
What are the participation requirements?
Inclusion Criteria
- Confirmed diagnosis of PSC
Exclusion Criteria
- Clinically significant acute or chronic liver disease of an etiology other than PSC
- Secondary or IgG4 related sclerosing cholangitis